Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04050280
Title CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Maryland, Baltimore
Indications

acute myeloid leukemia

Therapies

Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin

Gemtuzumab ozogamicin

Cladribine + Cytarabine + Filgrastim

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.